DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, has entered new contracts agreeing to deliver its digital therapeutics solutions for four employers; the new accounts are slated to being during the first half of 2022. According to the company, its new clients include a northeast regional employer that contracted for Dario’s diabetes solution and two educational organizations and a regional professional services firm opting for Dario’s behavioral health solution. These most recent contracts bring the total number of new contracts Dario has entered into in 2021 to 54, representing 40 clients; this is the first full year the company has offered digital therapeutics in the business-to-business market. The company’s solutions address common chronic conditions, including diabetes, hypertension, weight management, musculoskeletal, and behavioral health. “2022 is off to a strong start as Dario continues to experience quick growth with a total of seven new contracts in January 2022,” said Dario president and general manager, North America Rick Anderson in the press release. “The employer market increasingly seeks out Dario for our hyperpersonalized, integrated, multicondition digital therapeutic platform, and we are excited to see so many new customers launching on the platform over the next several months.”
To view the full press release, visit https://ibn.fm/vyoXf
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market, covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform. Dario’s next-generation, AI-powered, digital therapeutic platform supports more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions; intuitive, clinically proven digital tools; high-quality software; and coaching to help individuals improve health and sustain meaningful outcomes. Dario’s unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology and utilizes a performance-based approach to improve its users’ health. On the path to better health, Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
